DelistingMay 13, 2026, 08:07 AM
Reviva Pharmaceuticals Delisted from Nasdaq; Moves to OTCQB
AI Summary
Reviva Pharmaceuticals Holdings, Inc. announced its common stock will be delisted from The Nasdaq Capital Market due to non-compliance with the $1.00 minimum bid price requirement. Trading on Nasdaq will be suspended as of May 14, 2026. The company's common stock will begin trading on the OTCQB Venture Market under its existing symbol "RVPH" on the same date. This delisting is expected to negatively impact stock liquidity, market price, and the company's ability to raise equity financing and provide employee incentives.
Key Highlights
- Reviva Pharmaceuticals' common stock will be delisted from The Nasdaq Capital Market.
- The delisting is due to non-compliance with Nasdaq Listing Rule 5550(a)(2) requiring a minimum bid price of $1.00 per share.
- Trading on Nasdaq will be suspended as of the open of trading on May 14, 2026.
- The company's common stock will begin trading on the OTCQB Venture Market under its existing symbol "RVPH" on May 14, 2026.
- The delisting is expected to reduce liquidity and market price of the common stock.
- It may also negatively impact the company's ability to raise equity financing and provide equity incentives.
- The common stock will fall within the definition of a "penny stock," leading to more stringent broker rules.